Bruker (BRKR)
(Delayed Data from NSDQ)
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$64.54 USD
+0.81 (1.27%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $64.54 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth A Momentum C VGM
Zacks News
BRKR Stock Might Gain From the Newly Launched OptoVolt Module
by Zacks Equity Research
At the Neuroscience 2024 conference, Bruker released its latest OptoVolt module, which seamlessly integrates with Ultima 2Pplus microscope and NeuraLight 3D SLM.
Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors
by Zacks Equity Research
BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.
Here's Why You Should Retain BRKR Stock in Your Portfolio Now
by Zacks Equity Research
Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
by Zacks Equity Research
BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
by Zacks Equity Research
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Bruker (BRKR) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Bruker's (BRKR) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
by Zacks Equity Research
Bruker (BRKR) invests in NovAliX to accelerate advancements in drug discovery, combining cutting-edge biophysical methods and technologies to develop new treatments and enhance biopharma solutions.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
Compared to Estimates, Bruker (BRKR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bruker (BRKR) stock based on the movements in the options market lately.
Bruker (BRKR) Q2 Earnings Meet Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 0% and 0.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Mettler-Toledo and Bruker
by Zacks Equity Research
Mettler-Toledo and Bruker have been highlighted in this Industry Outlook article.
2 Instruments Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like MTD and BRKR are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Gear Up for Bruker (BRKR) Q2 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Bruker (BRKR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
by Zacks Equity Research
Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
by Zacks Equity Research
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT